PT Nanotech Indonesia Global Tbk (NANO) Fair Value & Analysis
Healthcare · ID · Market cap 141B IDR
Fair value as of: Jul 18, 2026
From 23 valuation models · updated 23 days ago
Fair value updated Jul 18, 2026, revised from 10.55 IDR to 9.05 IDR (−14.2%) since Jun 24, 2026. Share price +40.9% over the past month.
A solid business, but screening 71% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (12.11 IDR). The favourable scenario is already priced in.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
53‑month range 13.00 IDR – 176.00 IDR · fair‑value band 7.70 IDR – 12.11 IDR · the 31.00 IDR price screens above the 9.05 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 18, 2026.
Analysis
PT Nanotech Indonesia Global Tbk (NANO) currently trades at 31.00 IDR, while our model-based Fair Value estimate is 9.05 IDR, implying the stock looks roughly 70.8% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, PT Nanotech Indonesia Global Tbk generated revenue of 72.2B IDR at a net margin of 2.9%. Revenue declined 70.1% year over year. It earns a return on equity of 0.6%. Net debt stands at 15.7B IDR. Fundamentals as of Jul 18, 2026
Our scenario range runs from 7.70 IDR (bear case) to 12.11 IDR (bull case); at 31.00 IDR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 65% below its 52-week high and 55% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -71%, NANO screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: DCF Models (98.82 IDR) versus Economic Profit (7.99 IDR). Highest evidence: Growth DCF (80).
Notify me when NANO reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Nanotech Indonesia Global Tbk provides technology and engineering research and development services in Indonesia. The company operates in two segments, Service and Trading.
Full company description
PT Nanotech Indonesia Global Tbk provides technology and engineering research and development services in Indonesia. The company operates in two segments, Service and Trading. It engages in travel agencies, bureau, tourism, nature tourism information, management consulting, employment, and education businesses, as well as operates in the manufacturing and trading industries. The company was incorporated in 2019 and is headquartered in South Tangerang, Indonesia. PT Nanotech Indonesia Global Tbk is a subsidiary of PT Nanotech Investama Sedaya.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Nanotech Indonesia Global Tbk reported revenue of 72.2B IDR in FY2025 versus 26.8B IDR in FY2021, a compound +28.1%/yr. Reported net income was 2.1B IDR in FY2025, compounding +13.4%/yr from FY2021.
NANO screens 71% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare PT Nanotech Indonesia Global Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Nanotech Indonesia Global Tbk (NANO) overvalued or undervalued?
What is the fair value of NANO?
What is the quality score of NANO?
What is the revenue of PT Nanotech Indonesia Global Tbk (NANO)?
What is the net profit margin of NANO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Nanotech Indonesia Global Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.